Hormone Therapy for Transgender Patients May be Safer than Recognized, Mount Sinai Researcher Reports
Study Finds No Rise in Prolactin in Patients Receiving Estrogen Therapy for Up to Six Years
Levels of prolactin, a hormone associated with milk production, did not rise in a retrospective chart review of nearly 100 transgender (male to female) patients receiving feminizing hormone therapy, alleviating concerns about a possible side effect, a Mount Sinai researcher has found.
Estrogen, part of the standard feminizing hormone therapy regimen, can stimulate prolactin levels, and medical guidelines recommend routinely checking prolactin levels in transgender patients receiving hormone therapy. Although the over production of prolactin isn't life-threatening, it can impair vision and produce other side effects.
The study is the first to measure prolactin levels in transgender patients receiving the standard feminizing hormone therapy regimen that is used in the United States and is significant because it demonstrates that gender-affirming treatment for transgender people may be safer than recognized.
Results of the study will be published online in Endocrine Practice, the journal of the American Association of Clinical Endocrinologists, on Wednesday, May 2 at 6PM EST.
Researchers examined estrogen, testosterone, and prolactin levels from 98 transgender women treated with estrogen therapy at the Endocrinology Clinic at Boston Medical Center. Up to six years of data were available for some patients. The researchers found no elevated levels of prolactin in any of the patients.
“Our data suggests that there may be no significant rise in prolactin when transgender women are treated with estrogen and that it may be unnecessary to monitor prolactin in patients receiving this treatment,” said the study’s lead author, Joshua Safer, MD, Executive Director, Center for Transgender Medicine and Surgery at Mount Sinai.
Dr. Safer says that this study adds to the slim body of evidence-based literature in transgender medicine.
“Significant knowledge gaps exist across all of the subspecialties in transgender medicine and there is a lack of prospective robust research and representation of transgender-specific data in the core medical journals,” said Dr. Safer. “Studies like this improve our knowledge of the best ways to treat this population.”
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across seven hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube.